GenfitAct. News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.01.25	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
13.11.24	GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 (GlobeNewswire)
07.11.24	GENFIT Reports Third Quarter 2024 Financial Information (GlobeNewswire)
23.09.24	GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval (GlobeNewswire)
19.09.24	GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
26.07.24	GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis (GlobeNewswire)
09.07.24	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
17.06.24	GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH (GlobeNewswire)
10.06.24	GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis (GlobeNewswire)
29.05.24	GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 (GlobeNewswire)
22.05.24	GENFIT: May 22, 2024 Combined Shareholders Meeting Results (GlobeNewswire)
14.05.24	GENFIT Reports First Quarter 2024 Financial Information (GlobeNewswire)
25.04.24	GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) (GlobeNewswire)
15.04.24	GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents (GlobeNewswire)
05.04.24	GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F (GlobeNewswire)
04.04.24	GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
29.02.24	GENFIT Announces Revenues and Cash Position as of December 31, 2023 (GlobeNewswire)
15.01.24	GENFIT Announces 2024 Financial Calendar (GlobeNewswire)
11.01.24	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
08.12.23	GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) (GlobeNewswire)
07.12.23	Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC (GlobeNewswire)
06.12.23	GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials (GlobeNewswire)
16.11.23	GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023 (GlobeNewswire)
13.11.23	GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine (GlobeNewswire)
09.11.23	GENFIT Reports Third Quarter 2023 Financial Information (GlobeNewswire)
02.11.23	GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023 (GlobeNewswire)
26.09.23	GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology (GlobeNewswire)
20.09.23	GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
05.09.23	GENFIT to Participate in Upcoming Investor Conferences (GlobeNewswire)
10.08.23	GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications (GlobeNewswire)
12.07.23	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
30.06.23	Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease (GlobeNewswire)
07.06.23	GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
31.05.23	GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset (GlobeNewswire)
24.05.23	GENFIT: May 24, 2023 Combined Shareholders Meeting results (GlobeNewswire)
23.05.23	GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology (GlobeNewswire)
11.05.23	GENFIT Reports First Quarter 2023 Financial Information (GlobeNewswire)
09.05.23	GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program (GlobeNewswire)
27.04.23	GENFIT Announces Publication of Extra-Financial Performance Report 2022 (GlobeNewswire)
19.04.23	GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents (GlobeNewswire)
18.04.23	GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F (GlobeNewswire)
13.04.23	GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
28.02.23	GENFIT Announces Revenues and Cash Position as of December 31, 2022 (GlobeNewswire)
31.03.16	GENFIT to Begin Elafibranor Clinical Program in PBC (Businesswire)
16.11.15	GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input (Businesswire)
19.03.14	GENFIT: GFT505 Eliminates NASH and Fibrosis in a Clinically Relevant Disease Model (Businesswire)
22.12.09	Undisclosed Group Seeks to Discredit Genfit’s Clinical Drug Candidate GFT505 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’949.00	3.43 %	K V
Novartis	91.57	1.45 %	K V
Nestle	75.70	1.37 %	K V
Roche Hldg G	278.60	1.35 %	K V
Swisscom	512.50	1.28 %	K V
CieFinRichemont	169.40	-1.34 %	K V
Holcim	89.70	-1.67 %	K V
Logitech Intl	80.52	-2.42 %	K V
Part Grp Hldg	1’355.50	-2.45 %	K V
ABB	50.70	-6.11 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu GenfitAct.

Aktien Top/Flop

Meistgelesene Nachrichten